Cantor lifts Ultragenyx price target after FDA Fayuvi approval
TradingView News reports Cantor raised its price target after the U.S. FDA approved Fayuvi to treat children with Sanfilippo syndrome Type A; Ultragenyx (RARE) was in focus amid “price-target hikes.”
S. Food and Drug Administration (FDA) approval of Fayuvi for children with Sanfilippo syndrome Type A. The approval follows a major setback for the company just weeks earlier.